MIC-12

N/A

Report date: 2025/01/26 17:11:35

Base Information

Drug NameMIC-12
Drug Alias NameCLEC12A-Directed Tumor-Targeting Antibody (ABL Bio/Eberhard Karls University/German Cancer Research Center)CLEC12A immunocytokine (ABL Bio/Eberhard Karls university/German Cancer Research center)MIC-12
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-15 modulatorsC-Type lectin domain family 12 member A modulators
TargetsInterleukin-15C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEberhard Karls University Tübingen
China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)Abl Bio IncEberhard Karls University Tübingen
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A